ArticleJournal of diabetes research2026
Increased Urinary Extracellular Vesicles and Reduced Expression of NEDD4L in Patients With Type 2 Diabetes and Diabetic Nephropathy.
Article in Journal of diabetes research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Increased Urinary Extracellular Vesicles and Reduced Expression of NEDD4L in Patients With Type 2 Diabetes and Diabetic Nephropathy.Journal of diabetes research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Diabetic nephropathy (DN) is a leading cause of chronic kidney disease. Current diagnosis requires the persistent presence of albuminuria and/or reduction in estimated glomerular filtration rate, often detected only at late stages of disease. In recent years, extracellular vesicles (EVs), lipid bilayer membrane-enclosed particles that shed from cells, have gained momentum as a potential source of biomarkers for DN, reflecting pathological changes in this condition. Our previous work has demonstrated robust expression of the NEDD4L ubiquitin ligase in urinary EVs, with the loss of this protein in mice resulting in kidney disease. Reduced NEDD4L expression has been reported in the kidneys of patients with DN. Hence, in this study we analysed NEDD4L expression in kidney biopsies from patients with Type 2 diabetes mellitus (T2DM) and DN, as well as the release of urinary EVs from patients with DN and control subjects without diabetes. We assessed whether the level of NEDD4L in these vesicles reflects NEDD4L expression in kidney biopsy samples. Methods: Kidney biopsies (slides of control healthy kidney tissue taken adjacent to a suspected tumour site from five patients who had performed biopsy for suspicion of oncological pathology, and slides of kidney tissue from five patients with T2DM and DN) were utilised. Urine samples (from 21 control participants without diabetes, and from 21 patients with T2DM and DN) were collected. EVs were isolated and characterised from urine samples. NEDD4L protein expression levels were assessed in kidney biopsies and urinary EV samples. Results: Urine samples from patients with DN exhibited a heterogeneous population of EVs, with increased EV numbers and protein concentrations compared with controls without diabetes. Within EVs, NEDD4L protein expression was significantly reduced in patients with DN as compared with controls without diabetes. Conclusion: We reported a higher concentration of a heterogeneous population of urinary EVs in patients with T2DM and DN, with decreased NEDD4L protein levels that reflect the findings observed in the kidney biopsy samples of such patients. These findings support the potential use of urinary EVs as biomarkers of T2DM-related DN and suggest that lower NEDD4L levels within these vesicles may be an indicator of the extent of DN-associated tubular injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.